Endoscopic and imaging evaluations of neoadjuvant immunotherapy in patients with locally advanced colorectal cancer with dMMR/MSI-H or POLE/POLD1 mutation
摘要
In neoadjuvant immunotherapy, radiological assessment of pathological complete response (pCR) is frequently inaccurate, and atypical response patterns are occasionally observed. This study aims to investigate the diagnostic performance of new qualitative morphological changes for predicting pCR and to provide a comprehensive characterization of the imaging and endoscopic response patterns associated with neoadjuvant immunotherapy.
Materials and methodsA retrospective, single-center study was conducted to enroll consecutive patients with locally advanced colorectal cancer exhibiting dMMR/MSI-H or POLE/POLD1 mutation, who received first-line neoadjuvant immunotherapy. The diagnostic performance of the radiological complete response (rCR), morphological changes, endoscopy, and a combined model integrating morphological changes and endoscopy was assessed using the area under the receiver operating characteristic curve (AUC). Additionally, atypical response patterns and imaging features of immune-related adverse events (irAEs) were documented.
ResultsForty-three patients (mean age 53.84 ± 14.37; 23 males, 20 females) were included. Of these, 25 achieved pCR. Among pCR patients, 84% (21/25) had pseudoresidual disease. The combined model had a higher AUC than rCR and morphological changes alone, with numerical superiority over endoscopy alone (0.878 vs. 0.798, p = 0.07). Approximately 6.98% (3/43) of patients exhibited dissociated responses. Two cases of immunotherapy-induced Trousseau’s syndrome were identified.
ConclusionMorphological changes exhibit predictive value for pCR, and the combined model further shows promising potential. Pseudoresidual disease and dissociated responses are atypical but common response patterns in neoadjuvant immunotherapy. Accurate recognition of imaging features associated with various irAEs is crucial to prevent misinterpretation as metastatic disease.
Key Points